A multicenter, double-blind, placebo-controlled, randomised, parallel-group phase 3 study to evaluate the safety and efficacy of masitinib in patients with mild to moderate Alzheimer's disease

Trial Profile

A multicenter, double-blind, placebo-controlled, randomised, parallel-group phase 3 study to evaluate the safety and efficacy of masitinib in patients with mild to moderate Alzheimer's disease

Recruiting
Phase of Trial: Phase III

Latest Information Update: 09 Oct 2017

At a glance

  • Drugs Masitinib (Primary) ; Donepezil; Galantamine; Memantine; Rivastigmine
  • Indications Alzheimer's disease
  • Focus Registrational; Therapeutic Use
  • Sponsors AB Science
  • Most Recent Events

    • 21 Sep 2017 This trial has been suspended in Slovakia.
    • 09 Feb 2015 Planned number of patients changed from 396 to 600, according to an AB Science media release.
    • 09 Feb 2015 The Independent Data Safety Monitoring Committee has recommended continuation of the study, following successful completion of a futility analysis, according to an AB Science media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top